Department of Internal Medicine - Nephrology and Hypertension, Saarland University Medical Centre, Homburg/Saar, Germany.
Departments of Nephrology and Internal Medicine, Hochtaunus-Kliniken, Zeppelinstrasse 20, D-61352, Bad Homburg, Germany.
Crit Care. 2017 Nov 29;21(1):294. doi: 10.1186/s13054-017-1870-3.
As of 2009, anticoagulation with citrate was standard practice in continuous renal replacement therapy (CRRT) for critically ill patients at the University Medical Centre of Saarland, Germany. Partial hepatic metabolism of citrate means accumulation may occur during CRRT in critically ill patients with impaired liver function. The aim of this study was to evaluate the actual influence of hepatic function on citrate-associated complications during long-term CRRT.
In a retrospective study conducted between January 2009 and November 2012, all cases of dialysis therapy performed in the interdisciplinary surgical intensive care unit were analysed. Inclusion criteria were CRRT and regional anticoagulation with citrate, pronounced liver dysfunction, and pathologically reduced indocyanine green plasma disappearance rate (ICG-PDR).
A total of 1339 CRRTs were performed in 69 critically ill patients with liver failure. At admission, the mean Model for End-stage Liver Disease score was 19.2, and the mean ICG-PDR was 9.8%. Eight patients were treated with liver replacement therapy, and 30 underwent transplants. The mortality rate was 40%. The mean duration of dialysis was 19.4 days, and the circuit patency was 62.2 h. Accumulation of citrate was detected indirectly by total serum calcium/ionised serum calcium (tCa/iCa) ratio > 2.4. This was noted in 16 patients (23.2%). Dialysis had not to be discontinued for metabolic disorder or accumulation of citrate in any case. In 26% of cases, metabolic alkalosis occurred with pH > 7.5. Interestingly, no correlation between citrate accumulation and liver function parameters was detected. Moreover, most standard laboratory liver function parameters showed poor predictive capabilities for accumulation of citrate.
Our findings indicate that extra-hepatic metabolism of citrate seems to exist, avoiding in most cases citrate accumulation in critically ill patients despite impaired liver function. Because the citric acid cycle is oxygen-dependent, disturbed microcirculation would result in inadequate citrate metabolism. Raising the tCa/iCa ratio would therefore be an indicator of severity of illness and mortality rather than of liver failure. However, further studies are warranted for confirmation.
截至 2009 年,德国萨尔兰大学医学中心对危重病患者进行连续肾脏替代治疗(CRRT)时,使用柠檬酸盐进行抗凝是标准做法。柠檬酸盐的部分肝脏代谢意味着肝功能受损的危重病患者在进行 CRRT 时可能会发生蓄积。本研究旨在评估肝功能对长期 CRRT 期间柠檬酸盐相关并发症的实际影响。
在 2009 年 1 月至 2012 年 11 月期间进行的回顾性研究中,分析了在多学科外科重症监护病房进行的所有透析治疗病例。纳入标准为 CRRT 和局部柠檬酸盐抗凝、明显肝功能障碍和病理性吲哚菁绿血浆清除率(ICG-PDR)降低。
69 例肝功能衰竭的危重病患者共进行了 1339 次 CRRT。入院时,终末期肝病模型评分平均为 19.2,ICG-PDR 平均为 9.8%。8 例患者接受了肝替代治疗,30 例患者接受了移植。死亡率为 40%。透析的平均持续时间为 19.4 天,回路通畅时间为 62.2 小时。通过总血清钙/离子化血清钙(tCa/iCa)比值>2.4 间接检测到柠檬酸盐的蓄积。16 例(23.2%)患者出现这种情况。在任何情况下,都没有因代谢紊乱或柠檬酸盐蓄积而停止透析。在 26%的病例中,pH 值>7.5 时发生代谢性碱中毒。有趣的是,未检测到柠檬酸盐蓄积与肝功能参数之间存在相关性。此外,大多数标准实验室肝功能参数对柠檬酸盐蓄积的预测能力较差。
我们的发现表明,柠檬酸盐的肝外代谢似乎存在,尽管肝功能受损,大多数危重病患者仍避免了柠檬酸盐的蓄积。由于柠檬酸循环依赖于氧气,因此微循环紊乱会导致柠檬酸代谢不足。因此,tCa/iCa 比值的升高将成为疾病严重程度和死亡率的指标,而不是肝功能衰竭的指标。然而,还需要进一步的研究来证实这一点。